Production of recombinant adeno-associated virus vectors

Human Gene Therapy

Volumn 16, Issue 5, 2005, Pages 551-557

  Zolotukhin, Sergei ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HELICASE; PARVOVIRUS VECTOR; PROTEIN; PROTEIN CAP; UNCLASSIFIED DRUG;

BACULOVIRUS EXPRESSION SYSTEM; CELL DIFFERENTIATION; CLINICAL RESEARCH; DRUG SAFETY; GENE AMPLIFICATION; GENE EXPRESSION; GENETIC TRANSFECTION; GOOD MANUFACTURING PRACTICE; HELPER VIRUS; HERPES SIMPLEX VIRUS; NONHUMAN; PLASMID; REVIEW; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT;

ANIMALS; BACULOVIRIDAE; CELL LINE; DEPENDOVIRUS; GENETIC VECTORS; HELPER VIRUSES; HUMANS; PLASMIDS; RECOMBINATION, GENETIC; SEROTYPING; TRANSDUCTION, GENETIC; TRANSFECTION;

EID: 19644381507     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2005.16.551     Document Type: Review

References (57)

1. AURICCHIO, A., HILDINGER, M., O'CONNOR, E., GAO, G.P., and WILSON, J.M. (2001a). Isolation of highly infectious and pure adeno-associated virus type 2 vectors with a single-step gravity-flow column. Hum. Gene Ther. 12, 71-76.
2. AURICCHIO, A., O'CONNOR, E., HILDINGER, M., and WILSON, J.M. (2001b). A single-step affinity column for purification of serotype-5 based adeno-associated viral vectors. Mol. Ther. 4, 372-374.
3. BOOTH, M.J., MISTRY, A., LI, X., THRASHER, A., and COFFIN, R.S. (2004). Transfection-free and scalable recombinant AAV vector production using HSV/AAV hybrids. Gene Ther. 11, 829-837.
4. BRUMENT, N., MORENWEISER, R., BLOUIN, V., TOUBLANC, E., RAIMBAUD, I., CHEREL, Y., FOLLIOT, S., GADEN, F., BOULANGER, P., KRONER-LUX, G., MOULLIER, P., ROLLING, F., and SALVETTI, A. (2002). A versatile and scalable two-step ion-exchange chromatography process for the purification of recombinant adeno-associated virus serotypes 2 and 5. Mol, Ther. 6, 678-686.
5. CHADEUF, G., FAVRE, D., TESSIER, J., PROVOST, N., NONY, P., KLEINSCHMTDT, J., MOULLIER, P., and SALVETTI, A. (2000). Efficient recombinant adeno-associated virus production by a stable rep-cap HeLa cell line correlates with adenovirus-induced amplification of the integrated rep-cap genome. J. Gene Med. 2, 260-268.
6. CLARK, K.R. (2002). Recent advances in recombinant adeno-associated virus vector production. Kidney Int. 61(Suppl. 1), 9-15.
7. CLARK, K.R., VOULGAROPOULOU, F., FRALEY, D.M., and JOHNSON, P.R. (1995). Cell lines for the production of recombinant adeno-associated virus. Hum. Gene Ther. 6, 1329-1341.
8. CLARK, K.R., VOULGAROPOULOU, F., and JOHNSON, P.R. (1996). A stable cell line carrying adenovirus-inducible rep and cap genes allows for infectivity titration of adeno-associated virus vectors. Gene Ther. 3, 1124-1132.
9. CLARK, K.R., LIU, X., MCGRATH, J.P., and JOHNSON, P.R. (1999). Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses. Hum. Gene Ther. 10, 1031-1039.
10. CONWAY, J.E., ZOLOTUKHIN, S., MUZYCZKA, N., HAYWARD, G.S., and BYRNE, B.J. (1997). Recombinant adeno-associated virus type 2 replication and packaging is entirely supported by a herpes simplex virus type 1 amplicon expressing Rep and Cap. J. Virol. 71, 8780-8789.
11. CONWAY, J.E., RHYS, C.M., ZOLOTUKHIN, I., ZOLOTUKHIN, S., MUZYCZKA, N., HAYWARD, G.S., and BYRNE, B.J. (1999). High-titer recombinant adeno-associated virus production utilizing a recombinant herpes simplex virus type I vector expressing AAV-2 Rep and Cap. Gene Ther. 6, 986-993.
12. DAVIDOFF, A.M., NG, C.Y., SLEEP, S., GRAY, J., AZAM, S., ZHAO, Y., McINTOSH, J.H., KARIMIPOOR, M., and NATHWANI, A.C. (2004). Purification of recombinant adeno-associated virus type 8 vectors by ion exchange chromatography generates clinical grade vector stock. J. Virol. Methods 121, 209-215.
13. FARSON, D., HARDING, T.C., TAO, L., LIU, J., POWELL, S., VIMAL, V., YENDLURI, S., KOPRIVNIKAR, K., HO, K., TWITTY, C., HUSAK, P., LIN, A., SNYDER, R.O., and DONAHUE, B.A. (2004). Development and characterization of a cell line for large-scale, serum-free production of recombinant adeno-associated viral vectors. J. Gene Med. 6, 1369-1381.
14. FISHER, K.J., KELLEY, W.M., BURDA, J.F., and WILSON, J.M. (1996). A novel adenovirus-adeno-associated virus hybrid vector that displays efficient rescue and delivery of the AAV genome. Hum. Gene Ther. 7, 2079-2087.
15. GAO, G.P., QU, G., FAUST, L.Z., ENGDAHL, R.K., XIAO, W., HUGHES, J.V., ZOLTICK, P.W., and WILSON, J.M. (1998). High-titer adeno-associated viral vectors from a Rep/Cap cell line and hybrid shuttle virus. Hum. Gene Ther. 9, 2353-2362.
16. GAO, G., QU, G., BURNHAM, M.S., HUANG, J., CHIRMULE, N., JOSHI, B., YU, Q.C., MARSH, J.A., CONCEICAO, C.M., and WILSON, J.M. (2000), Purification of recombinant adeno-associated virus vectors by column chromatography and its performance in vivo. Hum. Gene Ther. 11, 2079-2091.
17. GAO, G., ALVIRA, M.R., SOMANATHAN, S., LU, Y., VANDENBERGHE, L.H., RUX, J.J., CALCEDO, R., SANMIGUEL, J., ABBAS, Z., and WILSON, J.M. (2003). Adeno-associated viruses undergo substantial evolution in primates during natural infections. Proc. Natl. Acad. Sci. U.S.A. 100, 6081-6086.
18. GAO, G.P., ALVIRA, M.R., WANG, L., CALCEDO, R., JOHNSTON, J., and WILSON, J.M. (2002a). Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl. Acad. Sci. U.S.A. 99, 11854-11859.
19. GAO, G.P., LU, F., SANMIGUEL, J.C., TRAN, P.T., ABBAS, Z., LYND, K.S., MARSH, J., SPINNER, N.B., and WILSON, J.M. (2002b). Rep/Cap gene amplification and high-yield production of AAV in an A549 cell line expressing Rep/Cap. Mol. Ther. 5, 644-649.
20. GIARD, D.J., AARONSON, S.A., TODARO, G.J., ARNSTEIN, P., KERSEY, J.H., DOSIK, H., and PARKS, W.P. (1973). In vitro cultivation of human tumors: Establishment of cell lines derived from a series of solid tumors. J. Natl. Cancer Inst. 51, 1417-1423.
21. GRIMM, D., and KAY, M.A. (2003). From virus evolution to vector revolution: Use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy. Curr. Gene Ther. 3, 281-304.
22. GRIMM, D., KERN, A., RITTNER, K., and KLEINSCHMIDT, J.A. (1998). Novel tools for production and purification of recombinant adenoassociated virus vectors, Hum. Gene Ther. 9, 2745-2760.
23. HAUCK, B., CHEN, L., and XIAO, W. (2003). Generation and characterization of chimeric recombinant AAV vectors. Mol. Ther. 7, 419-425.
24. INOUE, N., and RUSSELL, D.W. (1998). Packaging cells based on inducible gene amplification for the production of adeno-associated virus vectors. J. Virol. 72, 7024-7031.
25. JOHNSTON, K.M., JACOBY, D., PECHAN, P.A., FRAEFEL, C., BORGHESANI, P., SCHUBACK, D., DUNN, R.J., SMITH, F.I., and BREAKEFIELD, X.O. (1997). HSV/AAV hybrid amplicon vectors extend transgene expression in human glioma cells. Hum. Gene Ther. 8, 359-370.
26. KALUDOV, N., HANDELMAN, B., and CHIORINI, J.A. (2002). Scalable purification of adeno-associated virus type 2, 4, or 5 using ion-exchange chromatography. Hum. Gene Ther. 13, 1235-1243.
27. LIU, X.L., CLARK, K.R., and JOHNSON, P.R. (1999). Production of recombinant adeno-associated virus vectors using a packaging cell line and a hybrid recombinant adenovirus. Gene Ther. 6, 293-299.
28. LIU, X., VOULGAROPOULOU, F., CHEN, R., JOHNSON, P.R., and CLARK, K.R. (2000). Selective Rep-Cap gene amplification as a mechanism for high-titer recombinant AAV production from stable cell lines. Mol. Ther. 2, 394-403.
29. MATHEWS, L.C., GRAY, J.T., GALLAGHER, M.R., and SNYDER, R.O. (2002). Recombinant adeno-associated viral vector production using stable packaging and producer cell lines, Methods Enzymol. 346, 393-413.
30. MEGHROUS, J., AUCOIN, M.G., JACOB, D., CHAHAL, P.S., ARCAND, N., and KAMEN, A.A. (2005). Production of recombinant adeno-associated viral vectors using a baculovirus/insect cell sus pension culture system; From shake flasks to a 20-L bioreactor Biotechnol. Prog. 21, 154-160.
31. MIZUKAMI, H., OKADA. T., OGASAWARA, Y., MATSUSHITA, T., URABE, M., KUME, A., and OZAWA, K. (2004). Separate control of Rep and Cap expression using mutant and wild-type loxP sequences and improved packaging system for adeno-associated virus vector production. Mol. Biotechnol. 27, 7-14.
32. NAKAMURA, S., NAKAMURA, R., SHIBATA, K., KOBAYASHI, M., SAHARA, N., SHIGENO, K., SHINJO, K., NAITO, K., OHNISHI, K., KASAHARA, N., and IWAKI, Y. (2004). Development of packaging cell lines for generation of adeno-associated virus vectors by lentiviral gene transfer of trans-complementary components. Eur. J. Haematol. 73, 285-294.
33. NATSOULTS, G. (inventor); AVIGEN (assignee) (1997). High efficiency helper system for AAV vector production. U.S. Patent 5,622,856.
34. NONY, P., TESSIER, J., CHADEUF, G., WARD, P., GIRAUD, A., DUGAST, M., LINDEN, R.M., MOULLIER, P., and SALVETTI, A. (2001). Novel cis-acting replication element in the adeno-associated virus type 2 genome is involved in amplification of integrated rep-cap sequences. J. Virol. 75, 9991-9994.
35. OKADA, T., MIZUKAMI, H., URABE, M., NOMOTO, T., MATSUSHITA, T., HANAZONO, Y., KUME, A., TOBITA, K., and OZAWA, K. (2001). Development and characterization of an antisense-mediated prepackaging cell line for adeno-associated virus vector production. Biochem. Biophys. Res. Commun. 288, 62-68.
36. PARK, M.T., LEE, M.S., KIM, S.H., JO, E.C., and LEE, G.M. (2004). Influence of culture passages on growth kinetics and adenovirus vector production for gene therapy in monolayer and suspension cultures of HEK 293 cells. Appl. Microbiol. Biotechnol. 65, 553-558.
37. POTTER, M., CHESNUT, K., MUZYCZKA, N., FLOTTE, T., and ZOLOTUKHIN, S. (2002). Streamlined large-scale production of recombinant adeno-associated virus (rAAV) vectors. Methods Enzymol. 346, 413-430.
38. QIAO, C., LI, J., SKOLD, A., ZHANG, X., and XIAO, X. (2002a). Feasibility of generating adeno-associated virus packaging cell lines containing inducible adenovirus helper genes. J. Virol. 76, 1904-1913.
39. QIAO, C., WANG, B., ZHU, X., LI, J., and XIAO, X. (2002b). A novel gene expression control system and its use in stable, high-titer 293 cell-based adeno-associated virus packaging cell lines. J. Virol. 76, 13015-13027.
40. RABINOWITZ, J.E., BOWLES, D.E., FAUST, S.M., LEDFORD, J.G., CUNNINGHAM, S.E., and SAMULSKI, R.J. (2004). Cross-dressing the virion: The transcapsidation of adeno-associated virus serotypes functionally defines subgroups. J. Virol. 78, 4421-4432.
41. ROSE, J.A., and KOCZOT, F. (I972). Adenovirus-associated virus multiplication. VI Helper requirement for viral deoxyribonucleic acid and ribonucleic acid synthesis. J. Virol. 10, 1-8.
42. SALVETTI, A., OREVE, S., CHADEUF, G., FAVRE, D., CHEREL, Y., CHAMPION-ARNAUD, P., DAVID-AMELINE, J., and MOULLIER, P. (1998). Factors influencing recombinant adeno-associated virus production. Hum. Gene Ther. 9, 695-706.
43. SHIAU, A.L., LIU, P.S., and WU, C.L. (2005), Novel strategy for generation and titration of recombinant adeno-associated virus vectors. J. Virol. 79, 193-201.
44. SMITH, R.H., DING, C., and KOTIN, R.M. (2003). Serum-free production and column purification of adeno-associated virus type 5. J. Virol. Methods 114, 115-124.
45. SNYDER, R.O., and FLOTTE, T.R. (2002), Production of clinical-grade recombinant adeno-associated virus vectors. Curr. Opin. Biotechnol. 13, 418-423.
46. TAMAYOSE, K., HIRAI, Y., and SHIMADA, T. (1996), A new strategy for large-scale preparation of high-titer recombinant adeno-associated virus vectors by using packaging cell lines and sulfonated cellulose column chromatography. Hum. Gene Ther. 7, 507-513.
47. TOUBLANC, E., BENRAISS, A., BONNIN, D., BLOUIN, V., BRUMENT, N., CARTIER, N., EPSTEIN, A.L., MOULLIER, P., and SALVETTI, A. (2004). Identification of a replication-defective herpes simplex virus for recombinant adeno-associated virus type 2 (rAAV2) particle assembly using stable producer cell lines. J. Gene Med. 6, 555-564.
48. URABE, M., DING, C., and KOTIN, R.M. (2002). Insect cells as a factory to produce adeno-associated virus type 2 vectors. Hum. Gene Ther. 13, 1935-1943.
49. WALTERS, R.W., YI, S.M., KESHAVJEE, S., BROWN, K.E., WELSH, M.J., CHIORINI, J.A., and ZABNER, J. (2001). Binding of adeno-associated virus type 5 to 2,3-linked sialic acid is required for gene transfer. J. Biol. Chem. 276, 20610-20616.
50. WUSTNER, J.T., ARNOLD, S., LOCK, M., RICHARDSON, J.C., HIMES, V.B., KURTZMAN, G., and PELUSO, R.W. (2002). Production of recombinant adeno-associated type 5 (rAAV5) vectors using recombinant herpes simplex viruses containing rep and cap. Mol. Ther. 6, 510-518.
51. XIAO, X., LI, J., and SAMULSKI, R.J. (1998). Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J. Virol. 72, 2224-2232.
52. YANG, Q., CHEN, F., and TREMPE, J.P. (1994). Characterization of cell lines that inducibly express the adeno-associated virus Rep proteins. J. Virol. 68, 4847-4856.
53. ZEN, Z., ESPINOZA, Y., BLEU, T., SOMMER, J.M., and WRIGHT, J.F. (2004). Infectious titer assay for adeno-associated virus vectors with sensitivity sufficient to detect single infectious events. Hum. Gene Ther. 15, 709-715.
54. ZHANG, H.G., WANG, Y.M., XIE, J.F., LIANG, X., HSU, H.C., ZHANG, X., DOUGLAS, J., CURIEL, D.T., and MOUNTZ, J.D. (2001). Recombinant adenovirus expressing adeno-associated virus Cap and Rep proteins supports production of high-titer recombinant adeno-associated virus. Gene Ther. 8, 704-712.
55. ZHANG, X., and LI, C.Y. (2001). Generation of recombinant adenoassociated virus vectors by a complete adenovirus-mediated approach. Mol. Ther. 3, 787-792.
56. ZOLOTUKHIN, S., BYRNE, B.J., MASON, E., ZOLOTUKHIN, I., POTTER, M., CHESNUT, K., SUMMERFORD, C., SAMULSKI, R.J., and MUZYCZKA, N. (1999). Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther. 6, 973-985.
57. ZOLOTUKHTN, S., POTTER, M., ZOLOTUKHIN, I., SAKAI, Y., LOILER, S., FRAITES, T.J., Jr., CHIODO, V.A., PHILLIPSBERG, T., MUZYCZKA, N., HAUSWIRTH, W.W., FLOTTE, T.R., BYRNE, B.J., and SNYDER, R.O. (2002). Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 28, 158-167.